ICAD Inc（ICAD）财务数据ICADICAD Inc

ICAD Inc (ICAD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Subscription term licenses, accounting for 36.6% of total sales, equivalent to $1.78M. Other significant revenue streams include Services and support and Products and perpetual licenses. Understanding this composition is critical for investors evaluating how ICAD navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, ICAD Inc maintains a gross margin of 84.80%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -23.16%, while the net margin is -17.09%. These profitability ratios, combined with a Return on Equity (ROE) of -16.53%, provide a clear picture of how effectively ICAD converts its operational activities into shareholder value.

In the context of the broader market, ICAD competes directly with industry leaders such as ZJYL and AVR. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, ICAD's gross margin of 84.80% stands against ZJYL's 24.31% and AVR's 76.91%. Such benchmarking helps identify whether ICAD Inc is trading at a premium or discount relative to its financial performance.